The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
TransCode Therapeutics Inc(NASDAQ:RNAZ)


TransCode Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing drugs for treating metastatic disease. The Company's development pipeline includes TTX-MC138, TTX-siPD-L1 and TTX-RIGA, TTX-siLIN28B, and TCD-miR10b.
Founded: 2016
CEO / Co-Founder: Michael Dudley
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Share this website to your friends
TransCode Therapeutics Days Payable Outstanding ttm (DPO)
TransCode Therapeutics Op Cashflow Per Share ttm
TransCode Therapeutics Free Cashflow Per Share ttm
TransCode Therapeutics Cash Per Share ttm
TransCode Therapeutics (GAAP) P/E ratio ttm
TransCode Therapeutics P/B ratio ttm
No extra charts and metrics for this ticker.